Mark Kozloff to Prostate-Specific Antigen
This is a "connection" page, showing publications Mark Kozloff has written about Prostate-Specific Antigen.
Connection Strength
0.067
-
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395.
Score: 0.032
-
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol. 2012 Mar; 23(3):688-694.
Score: 0.020
-
Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. Cancer. 2006 Jun 01; 106(11):2459-65.
Score: 0.014